Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
#2105
Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.
Aim(s): To describe treatment durations of LA-SSA in patients with metastatic GEP-NET G1/G2 in Sweden.
Materials and methods: Data was obtained via linkage of nationwide registers. Patients diagnosed between 1 Jul 2005 and 31 Dec 2013 in Sweden who purchased LA-SSA at least once were included (n=446).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Berthon A
Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,
Keywords: metastatic, GEP-NET, somatostatin analogues, treatment,
To read the full abstract, please log into your ENETS Member account.